ArticlePloS one2016
Glucose Augments Killing Efficiency of Daptomycin Challenged Staphylococcus aureus Persisters.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Sequential eradication of bacterial persisters: integrating phytochemical pharmacology with microenvironment-responsive delivery strategies.Frontiers in microbiology · 2026Review
- Effects of Nutritional Conditions on Growth, Biofilm Formation, and Enterotoxin Production inInternational journal of molecular sciences · 2025Article
- Ultrasound-Mediated Antibiotic Delivery to In Vivo Biofilm Infections: A Review.Chembiochem : a European journal of chemical biology · 2024Review
- Quorum-sensing regulation of phenazine production heightensAntimicrobial agents and chemotherapy · 2024Article
- A Methylazanediyl Bisacetamide Derivative Sensitizes Staphylococcus aureus Persisters to a Combination of Gentamicin And Daptomycin.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Antibiotic heteroresistance and persistence: an additional aid in hospital acquired infections byFuture microbiology · 2024Review
- Article
- Variability in Adaptive Resistance ofAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Metabolites Potentiate Nitrofurans in Nongrowing Escherichia coli.Antimicrobial agents and chemotherapy · 2021Article
- Nanotheranostics: A Possible Solution for Drug-ResistantNanomaterials (Basel, Switzerland) · 2021Review
- Selection of the Amino Acid and Saccharide That Increase the Tetracycline Susceptibility ofFrontiers in veterinary science · 2021Article
- Removal of peptidoglycan and inhibition of active cellular processes leads to daptomycin tolerance in Enterococcus faecalis.PloS one · 2021Article
- Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).Scientific reports · 2020Article
- A Quantitative Survey of Bacterial Persistence in the Presence of Antibiotics: Towards Antipersister Antimicrobial Discovery.Antibiotics (Basel, Switzerland) · 2020Article
- Natural brominated phenoxyphenols kill persistent and biofilm-incorporated cells of MRSA and other pathogenic bacteria.Applied microbiology and biotechnology · 2020Article
- Reduced Growth ofFrontiers in microbiology · 2020Article
- Daptomycin Pore Formation and Stoichiometry Depend on Membrane Potential of Target Membrane.Antimicrobial agents and chemotherapy · 2019Article
- Intracavitary and Systemic Daptomycin for Successful Treatment of a Postpneumonectomy Intrathoracic Infection.Antimicrobial agents and chemotherapy · 2017Article
- Convergence of Staphylococcus aureus Persister and Biofilm Research: Can Biofilms Be Defined as Communities of Adherent Persister Cells?PLoS pathogens · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of Staphylococcus aureus in stationary growth phase with high doses of the antibiotic daptomycin (DAP) eradicates the vast majority of the culture and leaves persister cells behind. Despite resting in a drug-tolerant and dormant state, persister cells exhibit metabolic activity which might be exploited for their elimination. We here report that the addition of glucose to S. aureus persisters treated with DAP increased killing by up to five-fold within one hour. This glucose-DAP effect also occurred with strains less sensitive to the drug. The underlying mechanism is independent of the proton motive force and was not observed with non-metabolizable 2-deoxy-glucose. Our results are consistent with two hypotheses on the glucose-DAP interplay. The first is based upon glucose-induced carbohydrate transport proteins that may influence DAP and the second suggests that glucose may trigger the release or activity of cell-lytic proteins to augment DAP's mode of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.